CN114712393B - Application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer - Google Patents
Application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer Download PDFInfo
- Publication number
- CN114712393B CN114712393B CN202011501851.6A CN202011501851A CN114712393B CN 114712393 B CN114712393 B CN 114712393B CN 202011501851 A CN202011501851 A CN 202011501851A CN 114712393 B CN114712393 B CN 114712393B
- Authority
- CN
- China
- Prior art keywords
- mesenchymal stem
- liver cancer
- alpha
- hnf
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 87
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 78
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 56
- 101150003775 HNF1A gene Proteins 0.000 title abstract description 61
- 101150087698 alpha gene Proteins 0.000 title description 14
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 54
- 206010061218 Inflammation Diseases 0.000 claims abstract description 24
- 230000004054 inflammatory process Effects 0.000 claims abstract description 24
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 claims abstract description 18
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 17
- 102000009824 Hepatocyte Nuclear Factor 1-alpha Human genes 0.000 claims abstract description 16
- 102000008088 Hepatocyte Nuclear Factors Human genes 0.000 claims abstract description 5
- 108010049606 Hepatocyte Nuclear Factors Proteins 0.000 claims abstract description 5
- 230000014509 gene expression Effects 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 22
- 241000701161 unidentified adenovirus Species 0.000 claims description 21
- 239000013604 expression vector Substances 0.000 claims description 14
- 210000001185 bone marrow Anatomy 0.000 claims description 12
- 239000013603 viral vector Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 6
- 210000003954 umbilical cord Anatomy 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 210000004696 endometrium Anatomy 0.000 claims description 3
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 210000002826 placenta Anatomy 0.000 claims description 3
- 210000003074 dental pulp Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 40
- 238000011282 treatment Methods 0.000 abstract description 28
- 206010067125 Liver injury Diseases 0.000 abstract description 17
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 238000011161 development Methods 0.000 abstract description 13
- 231100000753 hepatic injury Toxicity 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000002980 postoperative effect Effects 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 4
- 238000011321 prophylaxis Methods 0.000 abstract description 4
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 69
- 241000700159 Rattus Species 0.000 description 31
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 30
- 230000000694 effects Effects 0.000 description 30
- 206010028980 Neoplasm Diseases 0.000 description 29
- 210000004185 liver Anatomy 0.000 description 22
- 238000001802 infusion Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 210000005228 liver tissue Anatomy 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 231100000504 carcinogenesis Toxicity 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 101150068639 Hnf4a gene Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000002293 adipogenic effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000029052 metamorphosis Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 2
- 206010000804 Acute hepatic failure Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000006754 Hepatocyte Nuclear Factor 1 Human genes 0.000 description 2
- 108010086512 Hepatocyte Nuclear Factor 1 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 231100000836 acute liver failure Toxicity 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004024 hepatic stellate cell Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101001045753 Rattus norvegicus Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 230000031142 liver development Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides application of a hepatocyte nuclear factor-1 alpha (Hepatocyte nuclear factor, hnf-1 alpha) gene modified mesenchymal stem cell in preventing and treating liver cancer and other diseases. The modified cells have the functions of inhibiting liver cancer, inhibiting liver fibrosis, repairing liver injury and/or inhibiting inflammation; the inhibition includes prophylaxis or treatment. The invention provides a new clinical treatment way for preventing and treating diseases such as liver cancer, is hopeful to be used for preventing and treating postoperative recurrence of liver cancer patients, and has good development prospect.
Description
Technical Field
The invention belongs to the field of biotechnology; more specifically, the invention relates to the application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver diseases such as liver cancer, and in particular provides a stem cell treatment scheme for preventing early postoperative recurrence and metastasis of liver cancer.
Background
Cancer remains a difficult disease to combat in humans. With advances in medicine, although surgery, chemotherapy, and radiation have been used with some success to cure (cure) cancers, new strategies are still needed.
Primary liver cancer (Primary hepatocellular carcinoma, PHC) is a common malignant tumor at position 5 and cancer cause of death at position 3 worldwide, the number of new liver cancer cases per year is about 55 ten thousand worldwide, and the incidence rate of the primary liver cancer has increased in recent years. China is a disaster area for liver cancer incidence, and the number of death caused by liver cancer is about 20 ten thousand per year. The best treatment means for early liver cancer is radical surgical excision. However, the postoperative recurrence and metastasis of liver cancer patients are very easy to occur, the recurrence rate of three years after the operation is about 40% -50%, and the recurrence rate of five years after the operation is 60% -70%.
Once recurrence of liver cancer occurs, a variety of follow-up means are clinically employed. Comprising the following steps: surgical excision is performed again, the operation can treat recurrent tumor, but the recurrent liver cancer focus is usually more than one, and the liver cancer can recur at multiple parts and liver segments; the liver is difficult to be resected in a large area in the secondary operation, and is also difficult to be resected cleanly; the second scheme is minimally invasive treatment, such as hepatic arterial chemoembolization, on the basis of which a chemotherapeutic drug is infused into the tumor by using iodized oil, and tumor cells are specifically killed; chemical ablation, usually under the guidance of B-ultrasonic or CT, is to inject absolute alcohol into the tumor to rapidly dehydrate the cells and denature and solidify proteins, so as to kill the tumor cells, but the current application of the method is relatively less; physical ablation, including radio frequency ablation and microwave ablation, kills tumor cells under the guidance of B ultrasonic or CT through the heat generation effect of the puncture needle; and more common radiotherapy and chemotherapy with different curative effects.
The above-mentioned conventional treatment schemes, although possibly improving the survival rate and quality of life of the patient to some extent, inevitably cause secondary wounds and damages to the patient; therefore, there is a need in the art to develop new treatments or adjuvant treatments that are intended to directly inhibit recurrence of liver cancer after surgery.
Disclosure of Invention
The invention aims to provide application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver diseases such as liver cancer.
In a first aspect of the invention there is provided the use of a recombinant mesenchymal stem cell or a culture thereof in the preparation of a composition for use in: inhibiting liver cancer, inhibiting liver fibrosis, repairing liver damage, and/or inhibiting inflammation, including prophylaxis or treatment; wherein the recombinant mesenchymal stem cell is a mesenchymal stem cell expressing exogenous hepatocyte nuclear factor 1 alpha (Hnf-1 alpha).
In a preferred embodiment, the expression is high or over-expression.
In another preferred embodiment, an expression construct comprising an expression cassette for hepatocyte nuclear factor 1 alpha is introduced into said mesenchymal stem cells.
In another preferred embodiment, the expression construct (expression vector) comprises: viral vectors, non-viral vectors.
In another preferred embodiment, the expression vector comprises a vector selected from the group consisting of: adenovirus vectors, lentiviral vectors or adeno-associated virus vectors.
In another preferred embodiment, the expression vector is an adenovirus vector.
In another preferred example, the mesenchymal stem cells include (but are not limited to) mesenchymal stem cells of a source selected from the group consisting of: bone marrow, umbilical cord, fat, cord blood, placenta, dental pulp, and endometrium.
In another preferred embodiment, the liver cancer comprises: primary liver cancer, liver cancer recrudescing after liver cancer operation, liver cancer with inflammation environment.
In another preferred embodiment, the composition is further used for: reduces hepatic stellate cell activation.
In another preferred embodiment, the composition is further used for: reducing infiltration of inflammatory cells in liver tissue.
In another preferred embodiment, the composition is further used for: reduce the level of pro-inflammatory factors in serum.
In another preferred embodiment, the pro-inflammatory factor comprises TNF- α, IFN- γ, IL-4 or IL-6.
In another preferred embodiment, the composition is further used for: an index of decreasing liver function in serum, the index comprising: glutamic pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST), total Bilirubin (TBIL), and bound bilirubin (DBIL) content.
In another aspect of the invention, a recombinant mesenchymal stem cell or cell culture is provided, the cell comprising exogenous hepatocyte nuclear factor 1α.
In a preferred embodiment, introducing an expression construct comprising an expression cassette for hepatocyte nuclear factor 1 alpha into said mesenchymal stem cells to obtain said recombinant mesenchymal stem cells; preferably, the expression construct (expression vector) comprises: viral vectors, non-viral vectors; more preferably, the expression vector comprises a sequence selected from the group consisting of: adenovirus vectors, lentiviral vectors or adeno-associated virus vectors; more preferably, the expression vector is an adenovirus vector.
In another aspect of the present invention, there is provided a method for preparing a recombinant mesenchymal stem cell, comprising expressing exogenous hepatocyte nuclear factor 1α in the mesenchymal stem cell; the recombinant mesenchymal stem cells are cells for inhibiting liver cancer, inhibiting liver fibrosis, repairing liver injury and/or inhibiting inflammation, and the inhibition comprises prevention or treatment.
In another aspect of the present invention, there is provided a composition for inhibiting liver cancer, inhibiting liver fibrosis, repairing liver damage and/or inhibiting inflammation comprising the recombinant mesenchymal stem cells or cell culture described above, and a pharmaceutically acceptable carrier, said inhibiting comprising preventing or treating.
In another aspect of the present invention, there is provided the use of hepatocyte nuclear factor 1 alpha for the preparation of recombinant mesenchymal stem cells having the effect of inhibiting liver cancer, inhibiting liver fibrosis, repairing liver damage and/or inhibiting inflammation, said inhibition comprising prophylaxis or treatment.
In another aspect of the invention, there is provided a kit for inhibiting liver cancer, inhibiting liver fibrosis, repairing liver damage and/or inhibiting inflammation, said inhibition comprising prophylaxis or treatment, said kit comprising said recombinant mesenchymal stem cells or cell culture, or said composition.
Other aspects of the invention will be apparent to those skilled in the art in view of the disclosure herein.
Drawings
FIG. 1 is a diagram showing the results of isolation and identification of primary mesenchymal stem cells of rat bone marrow and detection of successful preparation of Hnf-1 alpha over-expressed mesenchymal stem cells;
a: primary rat MSCs are isolated and cultured and identified by adipogenic osteogenic differentiation;
B-C: and (5) identifying the transfection efficiency and transfection effect of the Hnf-1 alpha over-expressed adenovirus in MSCs.
FIG. 2 is a study of the effect of Hnf-1 alpha gene modified MSCs on DEN-induced development of primary liver cancer in rats;
a: survival curves of DEN cancer-induced rats after different MSCs are dried;
b: tumor formation of rat liver and HE staining results;
c: number of liver tumors in rats of different treatment groups.
FIG. 3 is a graph showing the effect of Hnf-1. Alpha. Genetically modified mesenchymal stem cells on DEN-induced liver injury repair;
a: detecting serum transaminase and bilirubin of rats in different treatment groups in the tissue metamorphosis period before liver cancer occurs;
b: and detecting the expression of sirius red and alpha-SMA in the liver of rats in different treatment groups before the occurrence of liver cancer.
FIG. 4 shows the effect of Hnf-1 alpha gene modified mesenchymal stem cells on liver inflammatory response during liver cancer;
a: the HE staining results of the liver slices of the rats in different treatment groups in the tissue metamorphosis period before the liver cancer occurs;
b: detection of inflammatory factors in serum of rats of different treatment groups in the tissue metamorphosis period before liver cancer occurs.
FIG. 5 shows the effect of HNF-1A gene modified human umbilical cord derived MSCs infused at the early stage of DEN induced cancer on inhibiting the development of DEN induced liver cancer;
a: tumor formation of rat liver and HE staining results;
b: maximum tumor volume of liver of rats in different treatment groups.
Detailed Description
The present inventors have conducted intensive studies and have revealed that mesenchymal stem cells (mesenchymal stem cells, MSCs) modified with hepatocyte nuclear factor 1α (Hepatocyte nuclear factor, hnf-1α) have the effects of inhibiting liver cancer, inhibiting liver fibrosis, repairing liver injury and/or inhibiting inflammation, including prevention or treatment. The invention provides a new clinical treatment way for preventing and treating diseases such as liver cancer, is hopeful to be used for preventing and treating postoperative recurrence of liver cancer patients, and has good development prospect.
Terminology
As used herein, the term "exogenous" or "heterologous" refers to a relationship between two or more nucleic acid or protein (polypeptide) sequences from different sources, or a relationship between a nucleic acid or protein from different sources and a host cell. For example, if the combination of nucleic acid/protein and host cell is not normally naturally occurring, the nucleic acid is exogenous to the host cell. The particular sequence is "exogenous" to the cell or organism into which it is inserted.
As used herein, the term "expression cassette" refers to a gene expression system comprising all the necessary elements necessary for expression of a gene of interest, typically including the following elements: a promoter, a target gene sequence, and a terminator; in addition, signal peptide coding sequences and the like can be optionally included. These elements are operatively connected.
As used herein, the term "expression construct" or "expression construct" refers to a recombinant DNA molecule that comprises a desired nucleic acid coding sequence, which may comprise one or more gene expression cassettes. The "construct" is typically contained in an expression vector.
As used herein, the terms "operably linked" or "operably linked" refer to a functional spatial arrangement of two or more nucleic acid regions or nucleic acid sequences. For example: the promoter region is placed in a specific position relative to the nucleic acid sequence of the gene of interest such that transcription of the nucleic acid sequence is directed by the promoter region, whereby the promoter region is "operably linked" to the nucleic acid sequence.
As used herein, the term "comprising" means that the various ingredients may be applied together in a mixture or composition of the invention. Thus, the terms "consisting essentially of and" consisting of are encompassed by the term "containing. As used herein, the term "effective amount" or "effective dose" refers to an amount that is functional or active in and acceptable to a human and/or animal.
As used herein, a "pharmaceutically acceptable" ingredient is a substance that is suitable for use in humans and/or mammals without undue adverse side effects (such as toxicity, irritation, and allergic response), commensurate with a reasonable benefit/risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents.
Mesenchymal stem cells
Inflammation is one of the most important factors responsible for tumorigenesis or promoting tumor progression, and about 20% of malignant tumors are induced or promoted by inflammation. Hepatitis B virus carriers in China are nearly one hundred million, and most liver cancer patients develop from hepatitis. According to the "seed and soil" theory, the local microenvironment of the recurrent transfer target organ is one of the determining factors that influence whether recurrent transfer occurs.
The analysis of the present inventors proves that, after surgical excision of liver cancer in early stage, liver cancer is very susceptible to recurrent metastasis if the cause of liver injury is not removed and the liver is still in chronic inflammatory injury state. Such as weakening the inflammatory state of the target organ that favors metastasis formation, while the occurrence of metastasis can be reduced. The transfer recurrence after liver cancer operation mostly occurs in the residual liver after operation, so the inflammatory immune microenvironment state of the liver is a key factor affecting the prognosis of patients after liver cancer operation. The postoperative recurrence of liver cancer is caused by the selective expansion of disseminated tumor cells by residual liver after operation to form recurrent foci, or by the selective expansion of newly mutated cells to form new liver cancer foci. The inflammatory state of the residual liver after liver cancer operation is inversely related to the regeneration capacity, and the heavier the inflammatory response is, the worse the regeneration capacity is, and the more easily the tumor recurrence focus is formed. Thus, the inventors believe that treatment against liver inflammation helps to inhibit tumor recurrence and metastasis.
MSCs are a population of adult stem cells derived from mesoderm that have a high self-renewal capacity and multipotent differentiation potential. The method is relatively easy to obtain, the in vitro amplification culture technology is mature, and a certain research is clinically carried out at present, for example, the method is used for treating GvHD, autoimmune diseases, inflammation-related liver and kidney injury and other diseases.
Unlike traditional chemicals, MSCs are a living cell that interacts with the environment. Under certain conditions, MSCs may act as pro-inflammatory cells and cross-present soluble foreign antigens as part of their antigen presenting cell characteristics. Interferon-gamma stimulates bone marrow MSCs to up-regulate expression of MHC-II molecules and presents exogenous antigens to T cells. Pig experiments with acute liver failure have found that the severe inflammatory environment limits the effectiveness of MSCs because MSCs have a low survival rate in the severe inflammatory liver environment. MSCs fail to improve survival in patients with chronic acute liver failure with systemic inflammation, but reducing inflammation is clearly beneficial to improving the therapeutic effect of MSCs. In a multicenter clinical study of MSCs to treat childhood hormone refractory GVHD, MSCs are more effective in early intervention than in late treatment. These study data suggest that inflammatory microenvironment characteristics have a significant impact on the therapeutic efficacy of MSCs. More importantly, researches show that when dexamethasone hormone exists in the organism, the immunosuppressive property of MSCs is severely inhibited; the effect of MSCs treatment is also greatly compromised in this case as described above. The in vivo environment is complex, and the functions of MSCs show different effects in different environments. As such, although MSCs are becoming more and more important in clinical applications, most of the results of current clinical trials are not satisfactory for medical use.
In vivo experiments on MSCs show that the MSCs can be infused in early stage of cancer occurrence to relieve inflammatory reaction of liver tissues, and the MSCs have the effect of inhibiting tumor occurrence and development to a certain extent, but the effect is still not very remarkable.
In order to improve the inhibition of tumor by mesenchymal cells, the present inventors conducted extensive analytical studies to analyze a wide variety of genes and finally determined to modify MSCs with Hnf-1 a. MSCs have the characteristic of chemotaxis to the injury part, and under the stimulation of injury inflammation microenvironment, MSCs can play an immunosuppressive role to inhibit the inflammatory reaction of body overstimulation, and after Hnf-1 alpha modifies MSCs, the inhibition effect of MSCs on tumors can be remarkably improved.
In the present invention, MSCs include, but are not limited to, MSCs derived from bone marrow, fat, umbilical cord, cord blood, placenta, pulp, endometrium, etc. In a preferred embodiment of the invention, the MSCs are bone marrow derived MSCs.
Hepatocyte nuclear factor 1 alpha
The hepatocyte nuclear factor 1 alpha (Hepatocyte nuclear factor, hnf-1 alpha) is one of the members of the HNFs family, and plays an important role in promoting liver development and maintaining hepatocyte biological functions, including regulating liver function-related gene expression and participating in glycolipid metabolism and bile acid metabolism, in order to regulate transcription factors for the expression of many liver function genes. Recent studies indicate that HNF-1. Alpha. Exhibits low expression in human liver cancer tissues, but the cause of down-regulation of the expression is still unclear. Among the members of the HNFs family, there is also a class of members, namely HNF-4α. Although HNF-1. Alpha. And HNF-4. Alpha. Belong to the same large family, they are quite different in structure and function: HNF-4α is a zinc finger structural protein, and has the characteristics of a fat-soluble hormone receptor; reports prove that HNF-4 alpha is closely related to the occurrence and development of viral hepatitis; there are also studies that up-regulation of HNF-4 alpha expression is an important signaling event for gastric tumors, and antagonism of HNF-4 alpha has an anti-tumor effect (HNF 4 alpha is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer, glut, 2014).
The Hnf-1. Alpha. Of the present invention may be naturally occurring, e.g., it may be isolated or purified from a mammal. In addition, the Hnf-1 alpha can also be artificially prepared, for example, the recombinant Hnf-1 alpha can be produced according to the conventional genetic engineering recombinant technology, so as to be applied to experiments or clinic. In application, recombinant Hnf-1 alpha may be used. The Hnf-1 alpha comprises the full-length Hnf-1 alpha or the biological activity fragment thereof.
In a preferred manner, the amino acid sequence of Hnf-1. Alpha. May be substantially identical to the sequence shown in NM-012669 (rat) and NM-001530 (human). The corresponding nucleotide coding sequence can be conveniently obtained according to the amino acid sequence of Hnf-1 alpha.
Amino acid sequences of Hnf-1 alpha that are formed by substitution, deletion or addition of one or more amino acid residues are also included in the present invention. Hnf-1 alpha or a biologically active fragment thereof comprises a replacement sequence of a portion of a conserved amino acid, said amino acid replaced sequence not affecting its activity or retaining a portion of its activity. Appropriate substitutions of amino acids are well known in the art, which can be readily performed and ensure that the biological activity of the resulting molecule is not altered. These techniques recognize to one skilled in the art that in general, altering individual amino acids in an unnecessary region of a polypeptide does not substantially alter biological activity. See Watson et al, molecular Biology of The Gene, fourth edition, 1987,The Benjamin/Cummings Pub.Co.P224.
Biologically active fragments of Hnf-1. Alpha. Can also be used in the present invention. As used herein, the term "biologically active fragment of Hnf-1α" refers to a polypeptide that retains all or part of the function of the full length Hnf-1α. Typically, the biologically active fragment retains at least 50% of the activity of full length Hnf-1. Alpha. Under more preferred conditions, the active fragment is capable of retaining 60%, 70%, 80%, 90%, 95%, 99%, or 100% of the activity of full-length Hnf-1 alpha.
The present invention may also employ modified or improved Hnf-1 alpha, e.g., hnf-1 alpha modified or improved to promote its half-life, effectiveness, metabolism, and/or potency of the protein. The modified or improved Hnf-1 alpha may be a conjugate of Hnf-1 alpha, or it may comprise substituted or artificial amino acids. The modified or improved Hnf-1 alpha may be one that has little commonality with naturally occurring Hnf-1 alpha, but also has the effects of inhibiting (including preventing or treating) liver cancer, inhibiting liver fibrosis, repairing liver injury, and/or inhibiting inflammation. That is, some variants that do not affect the biological activity of Hnf-1. Alpha. Can be used in the present invention.
Hnf-1 alpha modified mesenchymal stem cells and application thereof
Based on the new findings of the present inventors, the present invention provides MSCs that are Hnf-1 α modified MSCs, or MSCs that overexpress Hnf-1 α. Preferred are MSCs over-expressed by Hnf-1 alpha.
In the present invention, polynucleotide sequences encoding over-expressed Hnf-1 alpha may be inserted into recombinant expression vectors to transform MSCs. A wide variety of plasmids and vectors can be used in the present invention, provided that they replicate and are stable within MSCs. An important feature of expression vectors is that they generally contain an origin of replication, a promoter, a marker gene and translational control elements. For example, the expression vector may include: viral vectors, non-viral vectors.
Methods well known to those skilled in the art can be used to construct expression vectors containing the polynucleotide sequence of Hnf-1 alpha and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, DNA synthesis techniques, in vivo recombinant techniques, and the like. The DNA sequence may be operably linked to an appropriate promoter in an expression vector to direct mRNA synthesis. The transformation vector also includes a ribosome binding site for translation initiation and a transcription terminator.
In some preferred embodiments, the expression vector includes (but is not limited to): adeno-associated virus, lentiviral vectors, adenoviral vectors, and the like. In a more preferred mode, the Hnf-1 alpha gene modified MSCs are obtained by transfecting MSCs with Hnf-1 alpha over-expressing adenovirus. For example, in the examples, the over-expressed adenovirus vector is named pAdeno-MCMV-Gene of interest-HA-P2A-EGFP. The invention adopts adenovirus vector to carry out the overexpression of target genes, and after the adenovirus transfects MSCs, hnf-1 alpha genes are highly expressed in the MSCs, thereby having high infection rate. Compared with other viral vectors, the adenovirus transduction efficiency is higher, stem cells in the division stage and the non-division stage can be efficiently infected, and the adenovirus transduction efficiency is higher because the adenovirus transduction efficiency is not integrated into chromosomes.
Based on the new findings of the invention, the invention also provides the application of the MSCs modified by the Hnf-1 alpha gene, which is used for inhibiting liver cancer, inhibiting liver fibrosis, repairing liver injury and/or inhibiting inflammation, or is used for preparing a pharmaceutical composition for inhibiting liver cancer, inhibiting liver fibrosis, repairing liver injury and/or inhibiting inflammation; the inhibition includes prevention and treatment. The liver cancer comprises: primary liver cancer, liver cancer recrudescing after liver cancer operation, liver cancer with inflammatory environment, etc.; particularly preferably, the liver cancer includes liver cancer that recurs after early liver cancer surgery. Different from the tumor implantation, the DEN cancer induction model can simulate primary liver cancer, and the liver cancer recrudesce after early liver cancer operation is relatively similar to the primary liver cancer in pathogenesis, so the invention uses a proper animal model to simulate the liver cancer recrudesce after early liver cancer operation, and demonstrates the technical effect of the Hnf-1 alpha modified mesenchymal stem cells.
Based on the novel discovery of the invention, the invention also provides the application of Hnf-1 alpha in preparing recombinant mesenchymal stem cells, wherein the recombinant mesenchymal stem cells have the effects of inhibiting liver cancer, inhibiting liver fibrosis, repairing liver injury and/or inhibiting inflammation.
Composition and method for producing the same
The invention also provides a composition comprising an effective amount (e.g., 10 4 -10 9 Individual cells/ML; preferred 10 5 -10 8 Individual cells/ML; more preferably, 10 6 -10 7 Individual cells/ML), said Hnf-1 alpha modified MSCs, and a pharmaceutically acceptable carrier.
Typically, the cells are formulated in a nontoxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is typically about 5 to 8, preferably about 6 to 8.
Pharmaceutically acceptable carriers can include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. In general, the pharmaceutical formulations should be compatible with the mode of administration, and the pharmaceutical compositions of the present invention may be formulated as injectable formulations, for example, using physiological saline or aqueous solutions containing glucose and other adjuvants, by conventional methods. The pharmaceutical compositions are preferably manufactured under sterile conditions. The amount of active ingredient administered is a therapeutically effective amount. The pharmaceutical preparation of the invention can also be prepared into sustained release preparation.
The effective amount of Hnf-1 alpha modified MSCs described herein may vary depending on the mode of administration, the severity of the disease to be treated, and the like. The selection of the preferred effective amount can be determined by one of ordinary skill in the art based on a variety of factors (e.g., by clinical trials). Such factors include, but are not limited to: pharmacokinetic parameters of the Hnf-1 alpha modified MSCs, such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated in the patient, the weight of the patient, the immune status of the patient, the route of administration, etc. Typically, separate doses may be administered several times per day, or the dose may be proportionally reduced, depending on the requirements of the therapeutic condition.
As a preferred mode of the invention, in a specific embodiment of the invention, a number of dosing regimens for animals such as mice are given. Conversion from an animal (e.g., murine) dosage to a dosage suitable for human administration is readily made by one skilled in the art. There have been some examples in the art of body surface area proportional relationships of laboratory animals and humans commonly used for dose scaling, such as those listed in table 1 below.
TABLE 1
As an example of the table look-up method of table 1, for example: dog dose is 10 mg/kg, total dog dose of 12 kg is 12×10 mg = 120 mg; looking up table 70 kg of human versus 12 kg of dog intersection is 3.1, so the dose of human (70 kg) = 120 mg x 3.1 = 372 mg. It should be understood that the manner of scaling between other species and humans can be analogized.
The invention also provides a kit for inhibiting liver cancer, inhibiting liver fibrosis, repairing liver injury and/or inhibiting inflammation, comprising: a container, and a recombinant mesenchymal stem cell or cell culture disposed in the container.
In addition, the kit/kit can also contain auxiliary materials, such as injection needle tubes and the like.
In addition, the kit/kit may further comprise instructions for use, describing methods of inhibiting liver cancer, inhibiting liver fibrosis, repairing liver injury, and/or inhibiting inflammation based on the combination of compounds of the present invention.
The invention has the beneficial effects that:
according to animal experiments, the gene modified MSCs related in the invention can achieve the effect of inhibiting the occurrence and development of liver cancer by remarkably relieving the inflammatory reaction of liver tissues after being infused before the mutation phase of DEN induced cancer, and have a certain curative effect on preventing early postoperative recurrence of liver cancer. Therefore, the application of the Hnf-1 alpha gene modified MSCs in preventing early liver cancer postoperative recurrence has good development prospect.
In the embodiment of the invention, the MSCs are subjected to modification transformation by using over-expression adenovirus transfection to enable the MSCs to express the Hnf-1 alpha gene. The Hnf-1 alpha gene modified MSCs have good immunity, and allogeneic MSCs can evade the elimination of an autoimmune system in vivo, so that allogeneic MSCs can replace self stem cells for tumor treatment; the Hnf-1 alpha gene modified MSCs have good tumor targeting property, can migrate and home to tumor tissues, and can transfer antitumor drugs or therapeutic genes to tumor cells and micrometastases thereof in a targeting manner, thereby playing a role in inhibiting the growth and proliferation of tumors. The invention solves the problem that tumor gene therapy can not be efficiently targeted and transferred and is safe.
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental procedures, which do not address the specific conditions in the examples below, are generally carried out according to conventional conditions such as those described in J.Sam Brookfield et al, molecular cloning guidelines, third edition, scientific Press, 2002, or according to the manufacturer's recommendations.
Example 1 isolation and identification of rat bone marrow Primary mesenchymal Stem cells and preparation of Hnf-1 alpha overexpressing mesenchymal Stem cells
In this example, mesenchymal stem cells derived from rat bone marrow (rBMSCs) were used as an example.
(1) Isolation and in vitro culture of rat bone marrow mesenchymal stem cells
And separating bone marrow MSCs from SD rat by using adherence culture method, and culturing in vitro. Male SD rats were anesthetized with 200-250g of 10% chloral hydrate, and after conventional sterilization, the femur was removed and placed in L-DMEM medium. In an ultra clean bench, the marrow cavity is flushed with L-DMEM medium, marrow suspension is collected, centrifuged for 5 minutes (1500 rpm), and discardedRemoving supernatant, collecting cell precipitate, adding L-DMEM+10% fetal calf serum+100U/mL penicillin+100U/mL streptomycin, and counting with a blood cell counting plate to 1×10 5 /cm 2 Inoculating into 10cm culture dish, inoculating into L-DMEM+10% foetal calf serum+l 00U/mL penicillin+l 00U/mL streptomycin, 37 ℃ and 5% CO 2 And (5) standing and culturing the incubator. After 72h inoculation, the whole amount of the liquid is changed to remove suspended cells, and the liquid is changed every 2-3 days according to the growth condition of the cells.
(2) Subculture of rat bone marrow mesenchymal stem cells
After the cells grow to be full of 85-90% of the bottom area of the culture bottle, the culture solution is removed by the suction tube, and the PBS is washed for 2 times. About 1mL of 0.25% trypsin solution was added, digested for 2 minutes at 37℃and observed under a microscope, after which cells were retracted into a short round shape, the digestion was stopped by adding a culture solution containing 10% fetal bovine serum. Gently blowing the cells with a suction tube until the adherent cells fall off, sucking the cell suspension at 1000rpm, and centrifuging for 5 minutes; cell pellet was prepared as single cell suspension in complete medium containing 10% fetal bovine serum according to 1:2, the cells at this time were called passage 1 cells (P1).
In the same way, the number 2-4 generation cells were treated according to the procedure 1:2, subculturing.
(3) Differentiation of rat bone marrow mesenchymal stem cells into osteoblasts and adipogenic cells
MSCs were packed at 2X 10 4 Individual/cm 2 Inoculating the cells into a 24-well plate, and after the cells reach 80% fusion; inducing the cells by using an osteogenic inducing solution and a lipogenic inducing solution, respectively. For adipogenic induction, after the induction solution is treated for 20 days, the cells are subjected to Oil red O (Oil red O) staining identification; for osteogenesis, after 2-3 weeks of treatment with the induction solution, the cells were stained with alizarin red and photographed under a microscope.
The staining results observed under the microscope showed that the primary isolated mesenchymal stem cells can successfully differentiate into adipogenic cells and osteoblasts, with multipotent differentiation potential, as shown in fig. 1A.
(4) Hnf-1 alpha over-expression adenovirus transfected rat mesenchymal stem cell
Establishment of overexpression adenovirus Ad-Hnf-1 alpha: the present inventors inserted the whole genome sequence of rat Hnf-1α (GenBank ID: NM-012669) into the middle of EcoRI and BamHI cleavage sites of plasmid pAdeno-MCMV-HA-P2A-EGFP (obtained from Sundaku Biotechnology (Shanghai) Co., ltd.) expression plasmid to construct Hnf-1α over-expression adenovirus plasmid, and then transfected HEK293 cells to prepare Hnf-1α over-expression adenovirus. The primers MCMV-F and EGFP-N-3 were subsequently used for amplification verification.
MCMV-F:GGTATAAGAGGCGCGACCAG(SEQ ID NO:1);
EGFP-N-3:CGTCGCCGTCCAGCTCGACCAG(SEQ ID NO:2)。
The third generation MSCs are prepared by the methods in the above (1) - (2) and are 12000/cm 2 Individual cells MSCs were seeded in 24-well plates; after 24 hours of inoculation, the original medium was replaced with 0.5mL serum-free medium containing 6. Mu.g/mL Polybrene, and then the overexpressed adenovirus Ad-Hnf-1α (Ad-GFP as a control virus) was added at MOI=20 to transfect MSCs. After 12h, the virus solution was discarded, washed 2 times, and fresh complete medium was added for cultivation. 48 hours after transfection, MSCs were observed for green fluorescence expression using a fluorescence microscope.
The fluorescence microscope results show that the transfection efficiency of the control viruses Ad-GFP and Ad-Hnf-1 alpha can reach more than 80 percent, as shown in figure 1B.
(5) Hnf-1 alpha expression level detection
After transfection of MSCs with Ad-Hnf-1. Alpha. Cells were collected for protein extraction experiments. After the Ad-Hnf-1 alpha is transfected into MSCs by adopting a Western Blot method, the expression condition of Hnf-1 alpha in the MSCs is detected from the protein level.
Experimental results show that after transfection of MSCs with Ad-Hnf-1α, the protein expression level of Hnf-1α in the cells is significantly up-regulated, as shown in FIG. 1C.
EXAMPLE 2 research on the effects of Hnf-1 alpha Gene-modified MSCs on the development of DEN-induced primary liver cancer in rats
After 20 SD rats were adaptively fed for one week, they were randomly divided into 4 groups of 5 animals each, namely, PBS infusion group (Ctrl), ad-GFP-MSCs infusion group (Ad-GFP-MSCs), ad-Hnf-1α -MSCs infusion group (Ad-Hnf-1α -MSCs) and Ad-Hnf-1α infusion group, and all the experimental animals were fed DEN water (0.1% diethylnitrosamine)Animals of each experimental group were injected by tail vein from the 4 th week of DEN cancer induction (early stage of cancer induction, or referred to as "period of metaplasia"), 1.5X10 6 Individual cells/individual/800 μl; control (Ctrl) infuses 800 μlpbs; the tail vein injection is carried out once every two weeks for three times. Then the DEN water is continuously fed until the period of 14 weeks is over, and the water is replaced by ordinary drinking water. Survival of rats in different treatment groups was recorded. At 16 weeks of DEN cancer induction, experimental animals were sacrificed and liver tissue was collected for general observation and HE staining.
Experimental results show that compared with a control MSCs group, the early infusion of Ad-Hnf-1 alpha-MSCs can remarkably improve the inhibition effect on the occurrence and development of liver cancer: from the survival of experimental animals, it can be seen that the survival time of rats infused with Ad-Hnf-1α -MSCs at an early stage far exceeded that of the blank control group, and there was also a significant difference compared with the Ad-GFP-MSCs group and Ad-Hnf-1α, as shown in FIG. 2A.
When the liver tissue specimens are obtained through general dissection, a plurality of obvious tumor blocks are visible to naked eyes in the liver of a rat in a control group DEN administration period of 16 weeks, but the liver of the rat infused with Ad-Hnf-1 alpha and Ad-GFP-MSCs still has visible tumor nodules, but the number and the size of the tumor nodules are smaller than those of the liver of the DEN group, and the liver of the rat infused with Ad-Hnf-1 alpha-MSCs almost has no macroscopic tumor blocks, so that the overall liver state is good; it was shown that infusion of Ad-Hnf-1. Alpha. -MSCs at the early stage of DEN induced cancer significantly inhibited the development of tumorigenesis, as shown in FIGS. 2B-C.
EXAMPLE 3 effect of Hnf-1 alpha Gene modified mesenchymal Stem cells on DEN-induced liver injury repair
After 15 SD rats were adaptively fed for one week, they were randomly divided into 3 groups of 5 animals each, namely, PBS infusion group (Ctrl), ad-GFP-MSCs infusion group (Ad-GFP-MSCs) and Ad-Hnf-1α -MSCs infusion group (Ad-Hnf-1α -MSCs), all experimental animals in the treatment group were fed DEN water (0.1% diethylnitrosamine), and each experimental animal was injected by tail vein from 3 weeks of DEN cancer induction, 1.5X10 6 Individual cells/individual/800 μl; control group was infused with 800 μl PBS; the tail vein injection is carried out once every two weeks for three times. The experimental animals were sacrificed at week 8 of DEN treatment and animal serum and liver tissue were collected for related detection.
The biochemical analysis results show that compared with the Ctrl control group, the contents of liver function indexes such as ALT, AST, TBIL and DBIL in the serum of the animals in the Ad-GFP-MSCs and Ad-Hnf-1 alpha-MSCs infusion group are reduced, but the liver function condition of the Ad-Hnf-1 alpha-MSCs infusion group is better, as shown in figure 3A. The results demonstrate that Ad-Hnf-1. Alpha. -MSCs have a greater protective effect on injured livers than Ad-GFP-MSCs.
The sirius red staining and immunohistochemical staining results showed a significant decrease in fibrous tissue and hepatic stellate cell activation compared to Ctrl control and Ad-GFP-MSCs, ad-Hnf-1 a-MSCs infused groups, as shown in figure 3B. This result demonstrates that infusion of Ad-Hnf-1. Alpha. -MSCs can significantly slow down DEN-induced liver fibrosis.
Example 4 Effect of Hnf-1 alpha Gene-modified mesenchymal Stem cells on liver inflammatory response during liver cancer
The inflammatory response state of liver tissue was examined using the DEN cancer-inducing animal serum and liver tissue specimens collected in example 3 at week 8.
First, observation by H & E staining pictures revealed less infiltration of inflammatory cells in liver tissue of the Ad-Hnf-1. Alpha. -MSCs infused group compared to the Ctrl control group and Ad-GFP-MSCs, as shown in FIG. 4A.
At the same time, animal serum was subjected to inflammatory factor detection using a suspension chip system (Bioplex kit, biorad). The results of the study showed that the levels of pro-inflammatory factors such as TNF- α, IFN- γ, IL-4, and IL-6 in serum of animals of the infusion group of Ad-Hnf-1α -MSCs were significantly reduced compared to the Ctrl control group and Ad-GFP-MSCs (FIG. 4B), suggesting a greater ability of Ad-Hnf-1α -MSCs to inhibit inflammatory responses than Ad-GFP-MSCs.
EXAMPLE 5 Effect of human HNF-1A Gene-modified human umbilical cord-derived mesenchymal Stem cells on development and progression of DEN-induced rat primary liver cancer
A model of DEN-induced liver cancer occurrence was constructed with reference to example 2. The experimental animals were divided into 3 groups of 5 animals each. Infusion experiments were started on the fourth week of DEN dosing, where control group (Ctrl) was infused with 800 μl PBS; whereas the Ad-GFP-hMSCs and the Ad-HNF-1A-hMSCs were infused with the corresponding cells 1.5X10 s, respectively 6 mu.L of each cell/800 mu.L, and the injection is carried out once every two weeks for tail vein, and three timesAnd twice. Then the DEN water is continuously fed until the period of 14 weeks is over, and the water is replaced by ordinary drinking water. On week 16 of DEN treatment, experimental animals were sacrificed and liver tissue was collected for general observation and HE staining.
As shown in FIG. 5, the infusion of HNF-1A gene modified human umbilical cord-derived MSCs at the early stage of DEN induced cancer also has the effect of significantly inhibiting the development of DEN induced liver cancer compared with the control group, similar to the case of rat MSCs.
All documents mentioned in this application are incorporated by reference as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the claims appended hereto.
Sequence listing
<110> third affiliated Hospital of the navy medical university of the free army of Chinese people
Application of <120> Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer
<130> 205279
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> Primer (Primer)
<400> 1
ggtataagag gcgcgaccag 20
<210> 2
<211> 22
<212> DNA
<213> Primer (Primer)
<400> 2
cgtcgccgtc cagctcgacc ag 22
Claims (10)
1. Use of recombinant mesenchymal stem cells in the preparation of a pharmaceutical composition for: inhibiting liver cancer, inhibiting liver fibrosis and inhibiting hepatitis; wherein the recombinant mesenchymal stem cell is a mesenchymal stem cell expressing exogenous hepatocyte nuclear factor 1 alpha and taking only the hepatocyte nuclear factor 1 alpha as an exogenous transcription factor.
2. The use according to claim 1, wherein an expression construct comprising an expression cassette for hepatocyte nuclear factor 1a is introduced into the mesenchymal stem cell, the expression construct comprising: viral vectors, non-viral vectors.
3. The use according to claim 1, wherein the expression construct is selected from the group consisting of: adenovirus vectors, lentiviral vectors or adeno-associated virus vectors.
4. The use according to claim 3, wherein the expression vector is an adenovirus vector.
5. The use according to claim 1, wherein the mesenchymal stem cells comprise mesenchymal stem cells of a source selected from the group consisting of: bone marrow, umbilical cord, fat, cord blood, placenta, dental pulp, and endometrium.
6. The use of claim 1, wherein the liver cancer comprises: primary liver cancer, liver cancer recrudescing after liver cancer operation, liver cancer with inflammation environment.
7. Use of a cell culture comprising recombinant mesenchymal stem cells expressing exogenous hepatocyte nuclear factor 1 alpha and having only hepatocyte nuclear factor 1 alpha as exogenous transcription factor for the preparation of a pharmaceutical composition for inhibiting liver cancer, inhibiting liver fibrosis and inhibiting hepatitis.
8. The use according to claim 7, wherein an expression construct comprising an expression cassette for hepatocyte nuclear factor 1a is introduced into the mesenchymal stem cell to obtain the recombinant mesenchymal stem cell, the expression construct comprising: viral vectors, non-viral vectors.
9. The use of claim 7, wherein said expression construct comprises a sequence selected from the group consisting of: adenovirus vectors, lentiviral vectors or adeno-associated virus vectors.
10. Use of a pharmaceutical composition comprising recombinant mesenchymal stem cells or cell cultures and a pharmaceutically acceptable carrier for the preparation of a kit for inhibiting liver cancer, inhibiting liver fibrosis and inhibiting hepatitis; the recombinant mesenchymal stem cell is a mesenchymal stem cell which expresses exogenous hepatocyte nuclear factor 1 alpha and takes only the hepatocyte nuclear factor 1 alpha as exogenous transcription factor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011501851.6A CN114712393B (en) | 2020-12-18 | 2020-12-18 | Application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011501851.6A CN114712393B (en) | 2020-12-18 | 2020-12-18 | Application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114712393A CN114712393A (en) | 2022-07-08 |
CN114712393B true CN114712393B (en) | 2024-01-19 |
Family
ID=82229865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011501851.6A Active CN114712393B (en) | 2020-12-18 | 2020-12-18 | Application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114712393B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010014949A2 (en) * | 2008-07-31 | 2010-02-04 | The General Hospital Corporation | Compositions comprising hepatocyte-like cells and uses thereof |
WO2011130402A2 (en) * | 2010-04-13 | 2011-10-20 | Cellular Dynamics International, Inc. | Hepatocyte production by forward programming |
WO2014121758A1 (en) * | 2013-02-08 | 2014-08-14 | Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences | Human hepatocyte-like cells and uses thereof |
CN109414460A (en) * | 2016-07-05 | 2019-03-01 | 詹森生物科技公司 | Retinal vascular disease is treated using progenitor cells |
-
2020
- 2020-12-18 CN CN202011501851.6A patent/CN114712393B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010014949A2 (en) * | 2008-07-31 | 2010-02-04 | The General Hospital Corporation | Compositions comprising hepatocyte-like cells and uses thereof |
WO2011130402A2 (en) * | 2010-04-13 | 2011-10-20 | Cellular Dynamics International, Inc. | Hepatocyte production by forward programming |
WO2014121758A1 (en) * | 2013-02-08 | 2014-08-14 | Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences | Human hepatocyte-like cells and uses thereof |
CN109414460A (en) * | 2016-07-05 | 2019-03-01 | 詹森生物科技公司 | Retinal vascular disease is treated using progenitor cells |
Non-Patent Citations (1)
Title |
---|
Overexpression of transcription factor Foxa2 and Hnf1a induced rat bone mesenchymal stem cells into hepatocytes;Yi Ding et al.;Cytotechnology;1-11 * |
Also Published As
Publication number | Publication date |
---|---|
CN114712393A (en) | 2022-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06508039A (en) | Recombinant defective adenovirus expressing cytokines for antitumor therapy | |
JP7378840B2 (en) | Oncolytic virus expressing interferon and its application | |
EA024878B1 (en) | Gene encoding human glucokinase mutant characterized by enhanced stability, and use thereof for controlling blood glucose or for preventing and treating disturbances of carbonydrate metabolism | |
CN106754723B (en) | Immune cell with anti-tumor function and application thereof | |
CN106167791B (en) | MSC-TNF alpha-AB stem cell and preparation method and application thereof | |
CN112190712A (en) | Application of combination of hydrosulfuryl oxidase 1 agonist and sorafenib in preparation of drugs for treating liver cancer cells | |
CN114712393B (en) | Application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer | |
CN108392492B (en) | Application of LDLR overexpression in NK cell adoptive therapy | |
CN109593725A (en) | A kind of recombination mescenchymal stem cell and its application | |
KR20230010617A (en) | Mesenchymal stem cells with oxidative stress resistance, manufacturing method and use thereof | |
KR102289661B1 (en) | Composition for preventing or treating Gout comprising stem cells overexpressing Uricase | |
AU2004240968B2 (en) | Recombinant gene medicine of adenovirus vector and gene p53 for treating proliferative diseases | |
CN111500632B (en) | Oncolytic adenovirus construction for expressing ST13 and TRAIL and application thereof | |
CN114432332A (en) | Application of circUTRN in preparation of medicine for treating heart failure, recombinant vector and medicine for treating heart failure | |
CN102660579A (en) | HBx and human IL-12 double-gene recombinant vector and liver caner-resistant vaccine | |
CN101744848B (en) | Application of FHL3 (four and a half LIM domains 3) in preparation of medicines for treating tumors | |
CN101683518B (en) | Application of FHL 1 in preparing medicament for treating tumour | |
CN105585637B (en) | Tumor therapeutic agent based on IL-12 stable membrane expression and preparation method and application thereof | |
CN117304343B (en) | Preparation and application of GPC3 targeted CAR-NK cells | |
US20050281785A1 (en) | Method of reducing side effects of cancer therapy using p53 recombinant adenovirus | |
NL2031110B1 (en) | Recombinant adeno-associated virus vector, recombinant adeno-associated virus aav8-pd1 and use thereof | |
CN111979204B (en) | Oncolytic vaccinia virus carrying sponge lectin gene, construction method and application | |
CN113355358B (en) | Preparation method and application of serum 9 type recombinant adeno-associated virus complexing agent | |
KR100492017B1 (en) | Method for anticancer treatment using human mesenhymal stem cell | |
KR20230095460A (en) | Mesenchymal stem cells overexpressing sFlt-1 having treating malignant melanoma and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |